FreeGuest Editorial Ukraine’s patients had to choose: What will kill you sooner? Cancer or artillery? February 24, 2023Vol.49 No.08By Anna Uzlova and Inessa Matiushenko
FreeGuest Editorial Ukraine’s cancer care system was in the midst of an overhaul—and then Russia invaded February 24, 2023Vol.49 No.08By Viacheslav Kopetskyi
Guest Editorial The anatomy of my decision to take a PAUSE and explore life outside the cancer center director’s office February 24, 2023Vol.49 No.08By George J. Weiner
FreeIn the Archives ‘The house that Jack built’: remembering Howard University’s Jack E. White February 24, 2023Vol.49 No.08By Robert A. Winn
Black History MonthCancer History Project MSK’s Vickers: “We’ve been seen as exclusive and selected. I want to broaden that aperture for the organization.” February 17, 2023Vol.49 No.07By Robert A. Winn
Grant-funded, investigator-initiated trials fail to bounce back from COVID as 50% of research staff left for higher-paying jobs February 17, 2023Vol.49 No.07By Matthew Bin Han Ong
Earthquake devastates Turkey and Syria, exacerbating Syria’s healthcare crisis February 17, 2023Vol.49 No.07By Jacquelyn Cobb
Regulatory News ODAC gives thumbs-up to GSK plan to build on MSK rectal cancer study of dostarlimab that produced 100% response February 10, 2023Vol.49 No.06By Jacquelyn Cobb and Paul Goldberg
Guest Editorial ODAC clears a path for dostarlimab, a drug that may “beat the reaper” in locally advanced rectal cancer February 10, 2023Vol.49 No.06By Richard M. Goldberg
